

**IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

In re Application of: Markussen, et al.

Application No.: To be assigned

Group Art Unit: To be assigned

Filed: July 16, 2003

Examiner: To be assigned

For: INSULIN DERIVATIVES

**INFORMATION DISCLOSURE STATEMENT**

Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

In accordance with 37 C.F.R. 1.56, 1.97 and 1.98, Applicants submit herewith references which they believe may be material to the patentability of this application and with respect to which there may be a duty to disclose in accordance with 37 C.F.R. 1.56.

While the references may be "material" under 37 C.F.R. 1.56, it is not intended to constitute an admission that the references are "prior art" unless specifically designated as such.

The filing of this Information Disclosure Statement shall not be construed as a representation that no material references other than those listed exist or that a search has been conducted.

The references are listed in Form PTO-1449 which is in accordance with the requirements of M.P.E.P. 609. Copies of references were filed with USSN's 08/448,210 08/932,082 and 09/861,687 filed on May 23, 1995, September 17, 1997 and May 21, 2001 respectively, the benefit of which is claimed under 35 USC 120.

The references are as follows:

1. EPO 0,712,861
2. EPO 0,712,862
3. WO 92/00321
4. EPO 0,376,156
5. US 5,506,202
6. WO 95/07931
7. Kodama et al., Abstract of Japan, Vol. 14, No. 7(C-673), (1988)
8. Muranishi et al., Abstract of Japan, Hei 1-254699 (October 11, 1989)


9. US 3,528,960
10. US 5,359,030
11. EPO 0 511 600 A2
12. WO 92/01476
13. WO 91/12817
14. JP 57-67548
15. GB 1 492 997
16. Samuel et al., (1978) Clin. Exp. Immunol. 33:252-260
17. Kurtz et al., (1983) Diabetologia 25:322-324
18. US 3,869,437
19. Markussen et al. Prot. Engineer. 2(2):157-166, 1988
20. Markussen et al. Prot. Engineer. 1(3):205-213, 1987
21. Harmann et al. Diabetes Res. Clin. Prac. 16: 175-181, 1992

It is respectfully requested that these references be considered by the Patent and Trademark Office in its examination of the above-identified application and be made of record therein. The Examiner is also invited to contact the undersigned if there are any questions concerning this paper or the attached references.

The information disclosure statement submitted herewith is being filed on filing date of application. Therefore, no fee is due. However, please charge any fees should they be required, to Novo Nordisk Pharmaceuticals, Inc. Deposit Account No. 14-1447.

Respectfully submitted,

Date: July 16, 2003

  
Richard W. Bork, Reg. No. 36,459  
Novo Nordisk Pharmaceuticals, Inc.  
100 College Road West  
Princeton, NJ 08540  
(609) 987-5800



23650

PATENT TRADEMARK OFFICE

FORM PTO-1449  
(Rev. 2-32)U.S. DEPARTMENT OF COMMERCE  
PATENT AND TRADEMARK OFFICE

Atty. Docket No. 4341.224-US

Serial No. T be assigned

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

Applicant Markussen et al.

(Use several sheets if necessary)

Filing Date July 16, 2003

Group T be assigned

## U.S. PATENT DOCUMENTS

EXAMINER INITIAL	DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	US 5,506,202	04/09/96	Vertesy, et al.	514	530	
	US 3,528,960	09/15/70	Hass et al.			
	US 5,359,030	10/25/94	Ekwuribe			

## FOREIGN PATENT DOCUMENTS

	DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
						YES	NO
	EPO 0 712,861	05/22/96	EPO				
	EPO 0 712,862	05/22/96	EPO				
	WO 92/00321	01/09/92	PCT				
	EPO 0,376,156	07/04/90	EPO				
	WO 95/07931	03/23/95	PCT				

## OTHER DOCUMENTS (Including Author, Title, Date, Pertinent Pages, Etc.)

		Kodama et al., Abstract of Japan, Vol. 14, No. 7 (C-673), (1988)
		Muranishi et al., Abstract of Japan, Hei 1-254699 (October 11, 1989)
		Samuel et al., (1978) Clin. Exp. Immunol. 33:252-260
		Kurtz et al., (1983) Diabetologia 25:322-324

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

